Neurotoxic consequences of central long-term administration of interleukin-2 in rats

Neuroscience

Volumn 79, Issue 3, 1997, Pages 799-818

  Hanisch, U K ^a,b   Neuhaus, J ^a   Rowe, W ^b   Van Rossum, D ^b   Moller T ^a   Kettenmann, H ^a   Quirion, R ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cytokines; Glia; IL 3; Neural immune; Neuroendocrine

Indexed keywords

CELL ADHESION MOLECULE; CORTICOSTERONE; CORTICOTROPIN; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FIBRONECTIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; RECOMBINANT INTERLEUKIN 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; AUTORADIOGRAPHY; B LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DEMYELINATION; EXTRACELLULAR MATRIX; FRONTAL CORTEX; HIPPOCAMPUS; HORMONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MAZE TEST; MEMORY; MICROGLIA; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; T LYMPHOCYTE;

ANIMALS; AUTORADIOGRAPHY; BRAIN; INJECTIONS, INTRAVENTRICULAR; INTERLEUKIN-2; MALE; MICROSCOPY, CONFOCAL; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0030844836     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00040-7     Document Type: Article

References (130)

1. Akiyama H., Tooyama I., Kondo H., Ikeda K., Kimura H., McGeer E. G., McGeer P. L. Early response of brain resident microglia to kainic acid-induced hippocampal lesions. Brain Res. 635:1994;257-268.
2. Allison J., Malcolm L., Chosich N., Miller J. F. Inflammation but not autoimmunity occurs in transgenic mice expressing constitutive levels of interleukin-2 in islet beta cells. Eur. J. Immunol. 22:1992;1115-1121.
3. 3H]dopamine in rat cultured mesencephalic cells. J. Neurochem. 61:1993;1284-1290.
4. Anderson T. D., Hayes T. J. Toxicity of human recombinant interleukin-2 in rats. Pathologic changes are characterized by marked lymphocytic and eosinophilic proliferation and multisystem involvement. Lab. Invest. 60:1989;331-346.
5. Anderson T. D., Hayes T. J., Powers G. D., Gately M. K., Tudor R., Rushton A. Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals. Int. Rev. exp. Path. 34(A):1993;57-77.
6. Araujo D. M. Contrasting effects of specific lymphokines on the survival of hippocampal neurons in culture. Adv. behav. Biol. 40:1992;113-122.
7. Araujo D. M., Lapchak P. A. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience. 61:1994;745-754.
8. Araujo D. M., Lapchak P. A., Collier B., Quirion R. Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: interaction with the cholinergic system. Brain Res. 498:1989;257-266.
9. Arzt E., Buric R., Stelzer G., Stalla J., Sauer J., Renner U., Stalla G. K. Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6. Endocrinology. 132:1993;459-467.
10. Aubert I., Rowe W., Meaney M. J., Gauthier S., Quirion R. Cholinergic markers in aged cognitively impaired Long-Evans rats. Neuroscience. 67:1995;277-292.
11. Awatsuji H., Furukawa Y., Nakajima M., Furukawa S., Hayashi K. Interleukin-2 as a neurotrophic factor for supporting the survival of neurons cultured from various regions of fetal rat brain. J. Neurosci. Res. 35:1993;305-311.
12. Balasingam V., Tejada Berges T., Wright E., Bouckova R., Yong V. W. Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines. J. Neurosci. 14:1994;846-856.
13. Banati R. B., Gehrmann J., Schubert P., Kreutzberg G. W. Cytotoxicity of microglia. Glia. 7:1993;111-118.
14. Banks W. A., Kastin A. J. The interleukins-1 alpha, -1 beta, and -2 do not acutely disrupt the murine blood-brain barrier. Int. J. Immunopharmac. 14:1992;629-636.
15. Benveniste E. N., Merrill J. E. Stimulation of oligodendroglial proliferation and maturation by interleukin-2. Nature. 321:1986;610-613.
16. Bernard J. T., Ameriso S., Kempf R. A., Rosen P., Mitchell M. S., Fisher M. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology. 40:1990;154-155.
17. Besedovsky H. O., del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr. Rev. 17:1996;64-102.
18. Bianchi M., Panerai A. E. Interleukin-2 enhances scopolamine-induced amnesia and hyperactivity in the mouse. NeuroReport. 4:1993;1046-1048.
19. Bindoni M., Perciavalle V., Beretta S., Belluardo N., Diamantstein T. Interleukin 2 modifies the bioelectric activity of some neurosecretory nuclei in the rat hypothalamus. Brain Res. 462:1988;10-14.
20. Bodnoff S. R., Humphreys A. G., Lehman J. C., Diamond D. M., Rose G. M., Meaney M. J. Enduring effects of chronic corticosterone treatment on spatial learning,synaptic plasticity, and hippocampal neuropathology in young and mid-aged rats. J. Neurosci. 15:1995;61-69.
21. Boiardi A., Silvani A., Ruffini P. A., Rivoltini L., Parmiani G., Broggi G., Salmaggi A. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol. Immunother. 39:1994;193-197.
22. Brunet J. M., Berger F., Gustin T., Laine M., Benabid A. L. Characterization of normal brain-reactive antibodies in glioma cyst fluids. J. Neuroimmunol. 47:1993;63-72.
23. Cambronero J. C., Rivas F. J., Borrell J., Guaza C. Interleukin-2 induces corticotropin-releasing hormone release from superfused rat hypothalami: influence of glucocorticoids. Endocrinology. 131:1992;677-683.
24. Caraceni A., Martini C., Belli F., Mascheroni L., Rivoltini L., Arienti F., Cascinelli N. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. Eur. J. Cancer. 29A:1993;1266-1269.
25. Carrieri P. B., Maiorino A., Provitera V., Soscia E., Perrella O. Cytokines in the pathogenesis of multiple sclerosis. Acta neurol. Napoli. 14:1992;333-341.
26. Cordier L., Duffour M. -T., Sabourin J. -C., Lee M. G., Cabannes J., Ragot T., Perricaudet M., Haddada H. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther. 2:1995;16-21.
27. Dalgleish A. G. A role of IL-2 in gene therapy. Gene Ther. 1:1994;83-87.
28. Davis E. J., Foster T. D., Thomas W. E. Cellular forms and functions of brain microglia. Brain Res. Bull. 34:1994;73-78.
29. De Sarro G., Nistico G. Effects of pertussis toxin, dibutyryl-cyclic-AMP, bromo-cyclic-AMP and forskolin on the behavioural and electrocortical power spectrum changes induced by microinfusion of interleukin-2 into the locus coeruleus. Int. J. Neurosci. 59:1991;67-79.
30. Denicoff K. D., Durkin T. M., Lotze M. T., Quinlan P. E., Davis C. L., Listwak S. J., Rosenberg S. A., Rubinow D. R. The neuroendocrine effects of interleukin-2 treatment. J. clin. Endocrinol. Metab. 69:1989;402-410.
31. Eckenstein F. P., Baughman R. W., Quinn J. An anatomical study of cholinergic innervation in rat cerebral cortex. Neuroscience. 25:1988;457-474.
32. Eddleston M., Mucke L. Molecular profile of reactive astrocytes - implications for their role in neurologic disease. Neuroscience. 54:1993;15-36.
33. Eitan S., Schwartz M. A transglutaminase that converts interleukin-2 into a factor cytotoxic to oligodendrocytes. Science. 261:1993;106-108.
34. Eitan S., Solomon A., Lavie V., Yoles E., Hirschberg D. L., Belkin M., Schwartz M. Recovery of visual response of injured adult rat optic nerves treated with transglutaminase. Science. 264:1994;1764-1768.
35. Eitan S., Zisling R., Cohen A., Belkin M., Hirschberg D. L., Lotan M., Schwartz M. Identification of an interleukin 2-like substance as a factor cytotoxic to oligodendrocytes and associated with central nervous system regeneration. Proc. natn. Acad. Sci. U.S.A. 89:1992;5442-5446.
36. Eizenberg O., Faber-Elman A., Gottlieb E., Oren M., Rotter V., Schwartz M. Direct involvement of p53 in programmed cell death of oligodendrocytes. Eur. molec. Biol. Org. J. 14:1995;1136-1144.
37. Eizenberg O., Faber-Elman A., Lotan M., Schwartz M. Interleukin-2 transcripts in human and rodent brains: Possible expression by astrocytes. J. Neurochem. 64:1995;1928-1936.
38. Ellison M. D., Merchant R. E. Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats. J. Neuroimmunol. 33:1991;245-251.
39. Forman A. D. Neurologic complications of cytokine therapy. Oncology (Williston Park). 8:1994;105-110.
40. Funke I., Prummer O., Schrezenmeier H., Hardt D., Weiss M., Porzsolt F., Arnold R., Heimpel H. Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation. Ann. Hematol. 68:1994;49-52.
41. Gaspari A. A. Autoimmunity as a complication of interleukin 2 immunotherapy. Archs Dermatol. 130:1994;894-898.
42. Gaykema R. P. A., Luiten P. M., Nyakas C., Traber J. Cortical projection patterns of the medial septum-diagonal band comlex. J. comp. Neurol. 293:1990;103-124.
43. Gehrmann J., Matsumoto Y., Kreutzberg G. W. Microglia: intrinsic immuneffector cell of the brain. Brain Res. Rev. 20:1995;269-287.
44. Giulian D. Reactive glia as rivals in regulating neuronal survival. Glia. 7:1993;102-110.
45. Giulian D., Li J., Li X., George J., Rutecki P.A. The impact of microglia-derived cytokines upon gliosis in the CNS. Devl Neurosci. 16:1994;128-136.
46. Giulian D., Woodward J., Young D. G., Krebs J. F., Lachman L. B. Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J. Neurosci. 8:1988;2485-2490.
47. Giulian D., Young D. G., Woodward J., Brown D. C., Lachman L. B. Interleukin-1 is an astroglial growth factor in the developing brain. J. Neurosci. 8:1988;709-714.
48. Goldsmith M. A. and Greene W. C. (1994) Interleukin-2 (IL-2). In Guidebook to Cytokines and their Receptors (ed. Nicola N. A.), pp. 27-30. Oxford University Press, Oxford.
49. Hanisch U. K., Lyons S., Kirchhoff F., Nolte C., Kettenmann H. O. Expression of a functional interleukin-15 receptor complex by microglial cells in culture. Soc. Neurosci. Abstr. 22:1996;849.
50. Hanisch U.-K., Quirion R. Interleukin-2 as a neuroregulatory cytokine. Brain Res. Rev. 21:1996;246-284.
51. Hanisch U.-K., Rothe T., Krohn K., Dykes R. W. Muscarinic cholinergic receptor binding in rat hindlimb somatosensory cortex following partial deafferentation by sciatic nerve transection. Neurochem. Int. 21:1992;313-327.
52. Hanisch U.-K., Rowe W., Sharma S., Meaney M. J., Quirion R. Hypothalamic-pituitary-adrenal activity during chronic central administration of interleukin-2. Endocrinology. 135:1994;2465-2472.
53. Hanisch U.-K., Rowe W., van Rossum D., Meaney M.J., Quirion R. Phasic hyperactivity of the HPA axis resulting from chronic central IL-2 administration. NeuroReport. 7:1996;2883-2888.
54. Hanisch U.-K., Seto D., Quirion R. Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2. J. Neurosci. 13:1993;3368-3374.
55. Heath W. R., Allison J., Hoffmann M. W., Schonrich G., Hammerling G., Arnold B., Miller J. F. Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature. 359:1992;547-549.
56. Hersi A. I., Richard J. W., Gaudreau P., Quirion R. Local modulation of hippocampal acetylcholine release by dopamine D1 receptors: a combined receptor autoradiography and in vivo dialysis study. J. Neurosci. 15:1995;7150-7157.
57. Hillhouse E. W. Interleukin-2 stimulates the secretion of arginine vasopressin but not corticotropin-releasing hormone from rat hypothalamic cells in vitro. Brain Res. 650:1994;323-325.
58. Hopkins S. J., Rothwell N. J. Cytokines and the nervous system I: expression and recognition. Trends Neurosci. 18:1995;83-88.
59. Huberman M., Shalit F., Roth Deri I., Gutman B., Brodie C., Kott E., Sredni B. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J. Neuroimmunol. 52:1994;147-152.
60. Issa A. M., Rowe W., Gauthier S., Meaney M. J. Hypothalamic-pituitary-adrenal activity in aged, cognitively impaired and cognitively unimpaired rats. J. Neurosci. 10:1990;3247-3254.
61. Jaradeh S., Schuelke G., Goldman R. S. Effects of in situ interleukin-2 on rat peripheral nerve. Soc. Neurosci. Abstr. 19:1993;504.
62. Kaneko K., Seki K., Ishida K., Uchihara T., Kanda T., Inuzuka T., Miyatake T. Circulating autoantibody to mature neurons and astrocytes of humans and some mammals present in a demented patient with autoimmune disorder. Eur. Neurol. 33:1993;450-453.
63. Karanth S., Krzysztof L., McCann S. M. Role of nitric oxide in interleukin 2-induced corticotropin-releasing factor release from incubated hypothalami. Proc. natn. Acad. Sci. U.S.A. 90:1993;3383-3387.
64. Karanth S., McCann S. M. Anterior pituitary hormone control by interleukin 2. Proc. natn. Acad. Sci. U.S.A. 88:1991;2961-2965.
65. Kent C., Clarke P. J. The immunolocalisation of the neuroendocrine specific protein PGP9.5 during neurogenesis in the rat. Devl Brain Res. 58:1991;147-150.
66. Kunicka J. E., Talle M. A., Denhardt G. H., Brown M., Prince L. A., Goldstein G. Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. Cell Immunol. 149:1993;39-49.
67. Lapchak P. A. A role for interleukin-2 in the regulation of striatal dopaminergic function. NeuroReport. 3:1992;165-168.
68. Lapchak P. A., Araujo D. M., Quirion R., Beaudet A. Immunoautoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivity) in the rat brain. Neuroscience. 44:1991;173-184.
69. Lissoni P., Barni S., Archili C., Cattaneo G., Rovelli F., Conti A., Maestroni G. J., Tancini G. Endocrine effects of a 24 hour intravenous infusion of interleukin-2 in the immunotherapy of cancer. Anticancer Res. 10:1990;753-757.
70. Lissoni P., Rovelli F., Tancini G., Tisi E., Rivolta M. R., Ardizzoia A., Brivio F. Inhibitory effect of interleukin-3 on interleukin-2-induced cortisol release in the immunotherapy of cancer. J. biol. Regul. homeost. Agents. 6:1992;113-115.
71. Martin R., Schwulera U., Menke G., Rudolph W., Buch K., Fasold H., Lissner R., Thrun A., Krauseneck P., Bogdahn U. Interleukin-2 and blood-brain barrier in cats: pharmacokinetics and tolerance following intrathecal and intravenous administration. Eur. Cytokine Netw. 3:1992;399-406.
72. McCann S. M., Karanth S., Kamat A., Les Dees W., Lyson K., Gimeno M., Rettori V. Induction by cytokines of the pattern of pituitary hormone secretion in infection. Neuroimmunomodulation. 1:1994;2-13.
73. McCutcheon I. E., Baranco R. A., Katz D. A., Saris S. C. Adoptive immunotherapy of intracerebral metastases in mice. J. Neurosurg. 72:1990;102-109.
74. McGeer P. L., McGeer E. G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:1995;195-218.
75. Mennicken F., Mazzoni I. E., Kenigsberg R. L., Quirion R. Interleukin-2 stimulates cholinergic neurons in septal cell cultures. Soc. Neurosci. Abstr. 20:1994;667.
76. Meyers C. A., Yung W. K. Delayed neurotoxicity of intraventricular interleukin-2: a case report. J. Neurooncol. 15:1993;265-267.
77. Michon J., Negrier S., Coze C., Mathiot C., Frappaz D., Oskam R., Pacquement H., Quintana E., Bouffet E., Bernard J. L.et al. Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-East of France Group Study. Prog. clin. Biol. Res. 385:1994;293-300.
78. Mucke L., Eddleston M. Astrocytes in infectious and immune-mediated diseases of the central nervous system. Fedn Am. Soc. exp. Biol. J. 7:1993;1226-1232.
79. Nemni R., Iannaccone S., Quattrini A., Smirne S., Sessa M., Lodi M., Erminio C., Canal N. Effect of chronic treatment with recombinant interleukin-2 on the central nervous system of adult and old mice. Brain Res. 591:1992;248-252.
80. Nieto Sampedro M., Chandy K. G. Interleukin-2-like activity in injured rat brain. Neurochem.Res. 12:1987;723-727.
81. Nistico G., De Sarro G. Behavioral and electrocortical spectrum power effects after microinfusion of lymphokines in several areas of the rat brain. Ann. N. Y. Acad. Sci. 621:1991;119-134.
82. Otero G. C., Merrill J. E. Cytokine receptors on glial cells. Glia. 11:1994;117-128.
83. Otero G. C., Merrill J. E. Molecular cloning of IL-2a, IL-2b, and IL-2R gamma cDNAs from a human oligodendroglioma cell line: presence of IL-2R mRNAs in the human central nervous system. Glia. 14:1995;295-302.
84. Park H. J., Won C. K., Pyun K. H., Shin H. C. Interleukin 2 suppresses afferent sensory transmission in the primary somatosensory cortex. NeuroReport. 6:1995;1018-1020.
85. Paxinos G. and Watson C. (1996) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego.
86. Petitto J. M., Huang Z. Molecular cloning of a partial cDNA of the interleukin-2 receptor-b in normal mouse brain: In situ localization in the hippocampus and expression by neuroblastoma cells. Brain Res. 650:1994;140-145.
87. Plata Salaman C. R., ffrench Mullen J. M. Interleukin-2 modulates calcium currents in dissociated hippocampal CA1 neurons. NeuroReport. 4:1993;579-581.
88. Porgador A., Feldman M., Eisenbach L. Immunotherapy of tumor metastasis via gene therapy. Natur. Immun. 13:1994;113-130.
89. Raber J., Bloom F. E. IL-2 induces vasopressin release from the hypothalamus and the amygdala: role of nitric oxide-mediated signaling. J. Neurosci. 14:1994;6187-6195.
90. Raber J., Bloom F. E. Arginine vasopressin release by acetylcholine or norepinephrine: region-specific and cytokine-specific regulation. Neuroscience. 71:1996;747-759.
91. Raber J., Koob G. F., Bloom F. E. Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response. J. Pharmac. exp. Ther. 272:1995;815-824.
92. Ram Z., Walbridge S., Heiss J. D., Culver K. W., Blaese R. M., Oldfield E. H. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J. Neurosurg. 80:1994;535-540.
93. Romeis (1989) Mikroskopische Technik. Urban and Schwarzenberg, München.
94. Rosenberg S. A., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J. Am. med. Ass. 271:1994;907-913.
95. Rosener M., Schwulera U., Menke G., Thrun A., Lissner R., Krauseneck P., Bogdahn U., Martin R. Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural interleukin-2: a phase I trial. Eur. Cytokine Netw. 4:1993;189-195.
96. Rothwell N. J., Hopkins S. J. Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci. 18:1995;130-136.
97. Rothwell N. J., Relton J. K. Involvement of cytokines in acute neurodegeneration in the CNS. Neurosci. Biobehav. Rev. 17:1993;217-227.
98. Saneto R. P., Altman A., Knobler R. L., Johnson H. M., De Vellis J. Interleukin 2 mediates the inhibition of oligodendrocyte progenitor cell proliferation in vitro. Proc. natn. Acad. Sci. U.S.A. 83:1986;9221-9225.
99. Sarder M., Saito H., Abe K. Interleukin-2 promotes survival and neurite extension of cultured neurons from fetal rat brain. Brain Res. 625:1993;347-350.
100. Saris S. C., Patronas N. J., Rosenberg S. A., Alexander J. T., Frank J., Schwartzentruber D. J., Rubin J. T., Barba D., Oldfield E. H. The effect of intravenous interleukin-2 on brain water content. J. Neurosurg. 71:1989;169-174.
101. Saris S. C., Spiess P., Lieberman D. M., Lin S., Walbridge S., Oldfield E. H. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J. Neurosurg. 76:1992;513-519.
102. Sawada M., Suzumura A., Marunouchi T. Induction of interleukin-2 receptor in mouse microglia. J. Neurochem. 64:1995;1973-1979.
103. Schattner A. Lymphokines in autoimmunity - a critical review. Clin. Immunol. Immunopath. 70:1994;177-189.
104. Schulte H. M., Bamberger C. M., Elsen H., Herrmann G., Bamberger A. M., Barth J. Systemic interleukin-1 alpha and interleukin-2 secretion in response to acute stress and to corticotropin-releasing hormone in humans. Eur. J. clin. Invest. 24:1994;773-777.
105. Selmaj K. W., Raine C. S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23:1988;339-346.
106. Semba K. and Fibiger H. C. (1989) Organization of central cholinergic systems. In Nicotinic Receptors in the CNS: Their Role in Synaptic Transmission (eds Nordberg A. et al.), pp. 37-63. Elsevier, Amsterdam.
107. Sessa M., Nemni R., Iannaccone S., Quattrini A., Confalonieri V., Canal N. In vivo modulation of myelin gene expression by human recombinant IL-2. Molec. Brain Res. 12:1992;331-334.
108. Shimojo M., Imai Y., Nakajima K., Mizushima S., Uemura A., Kohsaka S. Interleukin-2 enhances the viability of primary cultured rat neocortical neurons. Neurosci. Lett. 151:1993;170-173.
109. Singh V. K. Studies of neuroimmune markers in Alzheimer's disease. Molec. Neurobiol. 9:1994;73-81.
110. Smith L. R., Brown S. L., Blalock J. E. Interleukin-2 induction of ACTH secretion: presence of an interleukin-2 receptor alpha-chain-like molecule on pituitary cells. J. Neuroimmunol. 21:1989;249-254.
111. Sobol R. E., Fakhrai H., Shawler D., Gjerset R., Dorigo O., Carson C., Khaleghi T., Shiftan T. A., Royston I. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 2:1995;164-167.
112. Sunderkotter C., Steinbrink K., Goebeler M., Bhardwaj R., Sorg C. Macrophages and angiogenesis. J. Leukoc. Biol. 55:1994;410-422.
113. Tancredi V., Zona C., Velotti F., Eusebi F., Santoni A. Interleukin-2 suppresses established long-term potentiation and inhibits its induction in the rat hippocampus. Brain Res. 525:1990;149-151.
114. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science. 268:1995;251-255.
115. Theze J., Alzari P. M., Bertoglio J. Interleukin-2 and its receptors: recent advances and new immunological functions. Immunol. Today. 17:1996;481-486.
116. Tjuvajev J., Gansbacher B., Desai R., Beattie B., Kaplitt M., Matei C., Gilboa E., Blasberg R. RG-2 glioma growth attenuation and severe brain edema caused by localproduction of interleukin-2 and interferon-gamma. Cancer Res. 55:1995;1902-1910.
117. Tremblay N., Warren R. A., Dykes R. W. Electrophysiological studies of acetylcholine and the role of the basal forebrain in the somatosensory cortex of the cat. II. Cortical neurons excited by somatic stimuli. J. Neurophysiol. 64:1990;1212-1222.
118. Vassilopoulou Sellin R., Sella A., Dexeus F. H., Theriault R. L., Pololoff D. A. Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2. Horm. Metab. Res. 24:1992;434-438.
119. Vedeler C., Ulvestad E., Grundt I., Conti G., Nyland H., Matre R., Pleasure D. Fc receptor for IgG (FcR) on rat microglia. J. Neuroimmunol. 49:1994;19-24.
120. Vial T., Descotes J. Clinical toxicity of interleukin-2. Drug Saf. 7:1992;417-433.
121. Waguespack P. J., Banks W. A., Kastin A. J. Interleukin-2 does not cross the blood-brain barrier by a saturable transport system. Brain Res. Bull. 34:1994;103-109.
122. Waldmann T. A. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol. Today. 14:1993;264-270.
123. Wang F. Z., Yao H., Ding A. S. Effects of interleukin-1 and interleukin-2 on rat hippocampal neurons in culture. Soc. Neurosci. Abstr. 20:1994;1687.
124. Webster H. H., Hanisch U. K., Dykes R. W., Biesold D. Basal forebrain lesions with or without reserpine injection inhibit cortical reorganization in rat hindpaw primary somatosensory cortex following sciatic nerve section. Somatosens. Mot. Res. 8:1991;327-346.
125. Wells M. R., Racis S. P. Jr., Vaidya U. Changes in plasma cytokines associated with peripheral nerve injury. J. Neuroimmunol. 39:1992;261-268.
126. Whittington R., Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. 46:1993;446-514.
127. Wick G., Hu Y., Schwarz S., Kroemer G. Immunoendocrine communication via the hypothalamo-pituitary-adrenal axis in autoimmune diseases. Endocr. Rev. 14:1993;539-563.
128. Woodroofe M. N., Bellamy A. S., Feldmann M., Davison A. N., Cuzner M. L. Immunocytochemical characterization of the immune reaction in the central nervous system in multiple sclerosis. Possible role for microglia in lesion growth. J. neurol. Sci. 74:1986;135-152.
129. Zalcman S., Green-Johnson J. M., Murray L., Nance D. M., Dyck D., Anisman H., Greenberg A. H. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 643:1994;40-49.
130. Zier K., Gansbacher B., Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol. Today. 17:1996;39-45.